PSMC1P9: A Potential Drug Target and Biomarker for Proteasome-Mediated Cellular Signaling

Target Name: PSMC1P9

NCBI ID: G643668

PSMC1P9

Other Name(s): proteasome 26S subunit, ATPase 1 pseudogene 9 | Proteasome (prosome, macropain) 26S subunit, ATPase, 1 pseudogene 9 | Proteasome 26S subunit, ATPase 1 pseudogene 9

PSMC1P9: A Potential Drug Target and Biomarker for Proteasome-Mediated Cellular Signaling

Introduction

Proteasomes, large multiprotein complexes involved in protein degradation, play a crucial role in cellular signaling. The 26S subunit of the proteasome, also known as ATPase 1 (PMCA), is a key protein that functions as an ATP-dependent cytoplasmic protein kinase. PSMC1P9 , a specific pseudogene of the ATPase 1 gene, has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and neuropsychiatric disorders.

PSMC1P9 Localization and Functions

The 26S subunit of the proteasome is a 21-kDa protein that contains a N-terminal kinase domain, a transmembrane region, and a C-terminal protein-coding region. The N-terminal kinase domain is the site of the ATPase activity, which is responsible for generating ATP by phosphorylating the nucleotide. The C-terminal region contains a unique structural domain, known as the N-terminal hypervariable region (N-VHR), which is involved in protein-protein interactions and may play a role in regulating the assembly and function of the 26S subunit.

PSMC1P9 has been shown to localize to the cytoplasm and to interact with various cellular components, including other proteins involved in signaling pathways. It has been shown to participate in the negative regulation of cellular signaling by the TOR signaling pathway. This pathway is involved in cell growth, survival, and stress responses, and is a potential target for therapeutic intervention.

PSMC1P9 as a Drug Target

The TOR signaling pathway is a widely studied pathway involved in various cellular processes, including cell growth, differentiation, and stress responses. Disruptions in this pathway have been implicated in the development of several diseases, including cancer, neurodegenerative diseases, and neuropsychiatric disorders.

PSMC1P9 has been shown to be a potential drug target by its involvement in the TOR signaling pathway. Several studies have demonstrated that inhibition of the TOR pathway can lead to decreased levels of PSMC1P9 in cancer cells, leading to a reduction in cell proliferation and survival. Additionally, these studies have shown that inhibition of the TOR pathway can lead to increased levels of PSMC1P9 in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, suggesting a potential role for PSMC1P9 in the pathogenesis of these conditions.

PSMC1P9 as a Biomarker

PSMC1P9 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and neuropsychiatric disorders. Several studies have demonstrated that PSMC1P9 levels are elevated in various disease states, including cancer, neurodegenerative diseases, and neuropsychiatric disorders.

For example, several studies have shown that PSMC1P9 levels are increased in neuroendocrine tissues, such as the hypothalamus and pancreas, in response to various stimuli, including cancer. Additionally, these studies have shown that PSMC1P9 levels are increased in brain regions affected by neurodegenerative diseases , such as the brainstem and spinal cord, suggesting a potential role for PSMC1P9 in the pathogenesis of these conditions.

Conclusion

PSMC1P9 is a protein involved in the 26S subunit of the proteasome and has been shown to function as an ATP-dependent cytoplasmic protein kinase. Its localization to the cytoplasm and its interaction with various cellular components make it a potential drug target. Additionally, its involvement in the TOR signaling pathway and its potential as a biomarker for several diseases make it an attractive target for therapeutic intervention. Further research is needed to fully understand the role of PSMC1P9 in cellular signaling and its potential as a drug target and biomarker

Protein Name: Proteasome 26S Subunit, ATPase 1 Pseudogene 9

The "PSMC1P9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMC1P9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets